BioPlus바이오플러스
099430 · KOSDAQ · ₩099430 · 바이오플러스
₩3,410▲ ₩50 (1.49%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 68.7% | 66.7% | 64.2% | 60.8% | 59.6% | 63.2% |
| Operating margin | 17.9% | 16.5% | 35.6% | 43.1% | 44.6% | 48.7% |
| Net margin | 14.0% | 16.5% | 21.3% | 39.3% | 37.3% | 28.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +9.1% | +36.9% | +2.1% | +14.7% | +51.6% | — |
| Operating income growth | +18.2% | −36.6% | −15.6% | +10.9% | +38.7% | — |
| Net income growth | −7.7% | +6.0% | −44.7% | +21.0% | +97.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 7.8% | 9.7% | 10.8% | 21.2% | 22.0% | 13.6% |
| Return on assets | 4.1% | 7.3% | 8.0% | 17.2% | 17.6% | 12.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 48.1% | 46.2% | 78.9% | 25.2% | 27.5% | 9.9% |
| Net debt to equity | 16.0% | 14.7% | 9.1% | −44.1% | — | −49.1% |
| Current ratio | 94.8% | 83.8% | 68.4% | 887.8% | 1,119.1% | 725.6% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: BioPlus / 바이오플러스 / 099430 / KRX:099430
Source: KRX statistical information